The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia

Cost-effectiveness was estimated using the IQVIA CORE Diabetes Model, a web-based computer model that simulates the long-term health and economic outcomes of interventions for the treatment of type 1 and type 2 diabetes [35, 36]. Model outcomes include direct medical costs, life expectancy (measured in years), quality-adjusted life expectancy [measured in quality-adjusted life years (QALYs)], the cumulative incidence and time to onset of diabetes-related complications and cost-effectiveness scatterplots and acceptability curves. In cases where an intervention is associated with increased costs and greater clinical benefits, costs and effectiveness are combined to give an incremental cost-effectiveness ratio (ICER), describing the incremental cost per unit of effectiveness gained for the tested intervention versus the comparator. In scenarios where an intervention is associated with reduced costs and increased clinical benefits, it is considered dominant versus the comparator. The model has been validated versus real-life data at both the time of release in 2004 and more recently in 2014 and is frequently used and widely accepted by health technology assessment bodies globally [36, 37].

Analyses were performed over patient lifetimes, as per the guidelines for the assessment of cost-effectiveness of diabetes interventions, capturing all relevant long-term complications experienced by patients and the associated treatment costs [38]. All analyses utilized Slovakia-specific life tables for background mortality, with remaining mortality considered as a result of diabetes-related complications [39]. The risk of cardiovascular complications was predicted using the UKPDS 68 equations [40]. All base case and sensitivity analyses took a first-order Monte Carlo approach, while a second-order Monte Carlo approach was used for the probabilistic sensitivity analysis (PSA). Discounting for clinical and cost outcomes was set at 5.0% annually, in line with guidelines for health economic analyses in Slovakia [41].

Baseline cohort characteristics were based on the sub-group of patients with a BMI > 35 kg/m², extracted post-hoc from the SUSTAIN 7 clinical trial (Table 1). The number of cigarettes smoked per day and mean weekly alcohol consumption were unavailable from the trial data, and these were therefore based on Slovakia-specific data for the general population [42, 43].

Treatment effects relating to physiological parameters were also based on the sub-group of patients with a BMI > 35 kg/m² in SUSTAIN 7 (Table 2). While pre-specified analyses assessed the statistical significance of treatment effect differences between once-weekly semaglutide 1 mg and dulaglutide 1.5 mg, post-hoc analyses were required to assess the statistical significance of treatment effect differences between once-weekly semaglutide 0.5 mg and dulaglutide 1.5 mg. These showed that once-weekly semaglutide 0.5 mg was associated with non-statistically significant reductions in HbA1c, cholesterol and BMI, while once-weekly semaglutide 1 mg was associated with statistically significant reductions in HbA1c and BMI and non-statistically significant reductions in diastolic blood pressure and cholesterol compared with dulaglutide 1.5 mg. Both statistically significant and non-statistically significant differences were applied, in line with modeling guidelines [44].

Patients were modeled to receive once-weekly semaglutide or dulaglutide for the first 3 years of the analysis, based on a 2017 review of the current treatment landscape of type 2 diabetes, which reported that the average duration of GLP-1 receptor agonist treatment was 29.4 months [45]. As treatment switching is only possible at the end of a given year in the IQVIA CORE Diabetes Model, this was rounded up to 3 years. This approach is in line with previous long-term cost-effectiveness analyses of GLP-1 receptor agonists submitted to the Scottish Medicines Agency (SMC) and the National Institute for Health and Care Excellence (NICE) and published in peer reviewed journals [46‐51]. After 3 years, once-weekly semaglutide or dulaglutide treatment was discontinued, with patients intensifying to insulin glargine U100 (Abasaglar^®). This assumption recognizes the progressive nature of type 2 diabetes, with intensification to basal insulin therapy often needed for patients to maintain glycemic control in the long term.

Benefits in HbA1c and BMI with once-weekly semaglutide and dulaglutide were maintained during the 3 years patients received these treatments. Following intensification to basal insulin, HbA1c was brought to 7.0% in all treatment arms, as the baseline cohort characteristics justified an HbA1c target of 7.0%, according to ADA and EASD guidelines for glycemic targets in patients with type 2 diabetes (which recommend individualizing HbA1c targets based on patient factors), while BMI reverted to baseline for the remainder of patient lifetimes [52]. This resulted in a balanced cost-effectiveness analysis, with differences in HbA1c and BMI maintained only while there were differences in costs. Changes in blood pressure and serum lipids were assumed to follow the natural progression algorithms built into the IQVIA CORE Diabetes Model in all arms, based on the UKPDS or Framingham data (as described by Palmer et al.) [35]. Sensitivity analyses were conducted to explore alternate treatment switching approaches and parameter progression assumptions.

Costs were accounted from a Slovakian healthcare payer perspective and expressed in euros (EUR). Unit costs of diabetes medications and consumables were based on retail prices in Slovakia, with calculations reflecting the maximum reimbursement levels for needles and self-monitoring of blood glucose (SMBG) testing equipment for patients receiving basal insulin therapy, following treatment intensification.

Diabetes medication resource use was based on the sub-group of patients with a BMI > 35 kg/m² in the SUSTAIN 7 trial, including the ubiquitous use of concomitant metformin, which was priced according to a weighted average of metformin products used in Slovakia. No SMBG use was associated with once-weekly semaglutide or dulaglutide treatment. No needles were required for administration, as they are included in the once-weekly semaglutide and dulaglutide packs.

Following intensification after 3 years, patients were assumed to receive 40 IU insulin glargine U100 (Abasaglar), based on the defined daily dose (DDD), with universal concomitant metformin use continuing in all treatment arms. Patients were assumed to use the maximum number of reimbursable needles (200) and SMBG test strips (300) and lancets (100) annually. The impact of the cost of consumables was assessed in the sensitivity analyses, which removed consumables use for all treatment arms. Resource use was used to calculate annual treatment costs (Table 3).

Slovakia-specific costs of treating diabetes-related complications, in both the year of onset and annual follow-up costs, were identified from a published source [53]. Utilities relating to quality of life were taken from a 2014 review by Beaudet et al., with the exception of hypoglycemic event disutilities, which were sourced from a 2013 publication by Evans et al. (published after the literature searches by Beaudet et al. had been conducted) [54, 55].

Sensitivity analyses were conducted to test the robustness of the base case results, thereby examining the uncertainty associated with long-term extrapolation of clinical and cost outcomes from short-term data. An analysis was performed with only statistically significant differences between the treatment arms applied. The impact of shortening the time horizon was examined by conducting analyses with 10- and 20-year time horizons applied, for which it should be noted that not all diabetes-related complications and associated costs were captured, as the duration of the analyses was not sufficient for all patients to have died. The influence of discounting on cost and clinical outcomes was assessed by applying discount rates of 0% and 10% in separate simulations. The impact of differences in HbA1c on overall outcomes was evaluated in an analysis with only the difference in HbA1c between the treatment arms applied in the once-weekly semaglutide arms, with all other parameters equal to the dulaglutide arm.

Alternative HbA1c and BMI progressions were explored in separate analyses, with one applying the UKPDS progression equation for HbA1c in all treatment arms, with differences between the treatment arms gradually abolished, and the other assuming BMI differences between the treatment arms were maintained for patient lifetimes. Variations in treatment effects were assessed in separate analyses through application of the upper and lower limits of the 95% confidence intervals of the estimated treatment differences in HbA1c and BMI.

Alternative treatment switching approaches were evaluated by bringing forward treatment switching to the end of year 2 and pushing treatment switching back to the end of year 5 in all arms, as well as HbA1c progression following the UKPDS equations and treatment switching occurring when HbA1c exceeded 7.5%. The impact of over- or underestimating the costs of complications was assessed by increasing and decreasing these costs by 10% in separate analyses, while the influence of the costs of consumables (needles and SMBG testing) was tested by performing simulations with these costs excluded. Separate analyses were also conducted with alternative BMI and hypoglycemia disutilities applied, which gave greater impact to weight changes and non-severe hypoglycemic events, respectively [56, 57]. An additional analysis was performed with a diminishing hypoglycemia disutility model applied [58].

PSA, which captured statistical uncertainty by sampling around parameter inputs, was conducted with a second-order Monte Carlo approach using the predefined function in the IQVIA CORE Diabetes Model. Sampling was applied to baseline characteristics, treatment effects, event risks, costs and utilities.

This article does not contain any studies with human participants or animals performed by any of the authors.

Projections of long-term clinical outcomes in patients with a BMI > 35 kg/m² with inadequate glycemic control on OADs indicated that once-weekly semaglutide 0.5 mg and 1 mg were associated with improvements in discounted life expectancy of 0.04 and 0.06 years, respectively, and discounted quality-adjusted life expectancy of 0.04 and 0.07 QALYs, respectively, versus dulaglutide 1.5 mg (Table 4). Clinical benefits resulted from a reduced incidence and delayed time to onset of diabetes-related complications in the once-weekly semaglutide arms over the 50-year time horizon of the analysis. Benefits were observed across all included micro- and macrovascular complications (Fig. 1).

Long-term projections of direct medical costs suggested that the mean lifetime cost per patient was EUR 20 lower with once-weekly semaglutide 0.5 mg and EUR 140 lower with once-weekly semaglutide 1 mg versus dulaglutide 1.5 mg (Fig. 2). Treatment costs were EUR 20 and EUR 31 higher with once-weekly semaglutide 0.5 mg and 1 mg, respectively, versus dulaglutide 1.5 mg, as, despite equivalent unit costs, the increased survival and further treatment of patients over the long term led to increased expenditure. This was entirely offset by cost savings due to avoidance of diabetes-related complications, most notably ulcer, amputation and neuropathy complications and fewer severe hypoglycemic events with once-weekly semaglutide 0.5 mg (both yielding mean cost savings of EUR 16 per patient) and cardiovascular complications with once-weekly semaglutide 1 mg (yielding mean cost savings of EUR 128 per patient).

With both improved life expectancy and quality-adjusted life expectancy, achieved at a reduced cost from a healthcare payer perspective, once-weekly semaglutide 0.5 mg and 1 mg were considered dominant versus dulaglutide 1.5 mg.

Sensitivity analyses, conducted around model inputs and assumptions, showed that the base case findings were robust to changes in these parameters, with once-weekly semaglutide 0.5 mg and 1 mg remaining dominant versus dulaglutide 1.5 mg in the majority of scenarios (Table 5). Application of only statistically significant differences between the treatment arms led to no differences between the once-weekly semaglutide 0.5 mg and dulaglutide 1.5 mg arms, as all differences in treatment effects between these arms observed in SUSTAIN 7 were not significant, while once-weekly semaglutide 1 mg was associated with comparable clinical benefits and cost savings to the base case analysis and remained dominant. Application of 10- and 20-year time horizons reduced the clinical benefits associated with once-weekly semaglutide treatment, but both doses remained dominant versus dulaglutide 1.5 mg. These outcomes demonstrate how once-weekly semaglutide is associated with long-term benefits, not all of which are captured with shorter time horizons. Altering the discount rate also reflected this, with clinical benefits for both doses of once-weekly semaglutide greatly increased with discount rates of 0% applied. Once-weekly semaglutide 1 mg remained cost saving and dominant, but once-weekly semaglutide 0.5 mg was associated with small cost increases, yielding an ICER of EUR 160 per QALY gained. Applying discount rates of 10% decreased the clinical benefits associated with once-weekly semaglutide 0.5 mg and 1 mg, but both remained cost saving and dominant versus dulaglutide 1.5 mg.

Analyses conducted with only the treatment differences in HbA1c applied showed that these reductions were a substantial contributor to overall clinical outcomes, with both doses of once-weekly semaglutide remaining dominant versus dulaglutide 1.5 mg. Maintaining the BMI differences after treatment intensification to cover patient lifetimes resulted in increased incremental clinical benefits with once-weekly semaglutide, with incremental costs remaining similar to the base case analysis. Modeling HbA1c using the UKPDS progression equation following application of treatment effects in the first year of the analysis led to decreased quality-adjusted life expectancy in all treatment arms, but both doses of once-weekly semaglutide remained dominant.

Applying the upper limit of the 95% confidence interval of the estimated treatment differences in HbA1c resulted in maintained incremental benefits from the base case for once-weekly semaglutide 0.5 mg and increased incremental benefits for once-weekly semaglutide 1 mg, while use of the lower limit led to decreased clinical benefits for both doses. Application of the upper limit for differences in BMI resulted in increased incremental benefits for both once-weekly semaglutide 0.5 mg and 1 mg, while use of the lower limit had the opposite effect, with benefits reduced.

Bringing treatment switching forward to the end of year 2 resulted in reduced clinical benefits for once-weekly semaglutide 0.5 mg and 1 mg, but both remained dominant versus dulaglutide 1.5 mg. Pushing treatment switching back to the end of year 5 led to reduced incremental clinical benefits for once-weekly semaglutide 0.5 mg but increased clinical benefits for once-weekly semaglutide 1 mg, and both remained cost saving and dominant versus dulaglutide 1.5 mg. Applying the UKPDS progression equation and having treatment switching occur when HbA1c exceeded 7.5% resulted in reduced clinical benefits but increased cost savings for once-weekly semaglutide 0.5 mg and greater clinical benefits but increased incremental costs for once-weekly semaglutide 1 mg, yielding an ICER of EUR 3137 per QALY gained.

Increasing and decreasing the costs of complications by 10% resulted in only minor changes to incremental cost outcomes, and both doses of once-weekly semaglutide remained dominant. Similarly, excluding the costs of complications did not drastically alter cost outcomes, and once-weekly semaglutide 0.5 mg and 1 mg remained dominant versus dulaglutide 1.5 mg. Use of alternative disutilities for BMI and hypoglycemia resulted in only minor changes to clinical outcomes, and both doses of once-weekly semaglutide remained dominant versus dulaglutide 1.5 mg.

PSA, performed with sampling around cohort characteristics, treatment effects, complication costs and utilities, displayed comparable mean outcomes to the base case analysis, but yielded increased measures of variance around the mean results (Fig. 3). The mean incremental improvements in quality-adjusted life expectancy with once-weekly semaglutide 0.5 mg and 1 mg were 0.02 and 0.07 QALYs, respectively, versus dulaglutide 1.5 mg. Mean costs were estimated to be EUR 9 higher with once-weekly semaglutide 0.5 mg and EUR 93 lower with once-weekly semaglutide 1 mg versus dulaglutide 1.5 mg. Therefore, once-weekly semaglutide 0.5 mg was associated with an ICER of EUR 401 per QALY gained, while once-weekly semaglutide 1 mg was considered dominant versus dulaglutide 1.5 mg in the PSA. Based on a willingness-to-pay threshold of EUR 25,536 per QALY gained (the lowest possible threshold for an intervention in 2018, 28 times the average monthly wage in Slovakia), the modeling analysis indicated that the probabilities of once-weekly semaglutide 0.5 mg and 1 mg being cost-effective were 57.1% and 72.4%, respectively, versus dulaglutide 1.5 mg.